Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Recent Advances in Pharmacotherapeutic Paradigm of Mild to Recalcitrant Atopic Dermatitis

Volumen 33, Edición 3, 2016, pp. 213-263
DOI: 10.1615/CritRevTherDrugCarrierSyst.2016015219
Get accessGet access

SINOPSIS

Atopic dermatitis (AD) is a common, chronic skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin E (IgE), T lymphocytes, and mast cells. The key factors responsible for the pathophysiology of this disease are immunological disorders and defects in epidermal barrier properties. Pruritus, intense itching, psychological stress, deprived physical and mental performance, and sleep disturbance are the hallmark features of this dermatological disorder. Preventive interventions such as educational programs, avoidance of allergens, and exclusive care toward the skin could play a partial role in suppressing the symptoms. Based on the available clinical evidence, topical corticosteroids (TCs) are among the most commonly prescribed agents; however, these should be selected with care. In cases of steroid phobia, persistent adverse effects or chronic use, topical calcineurin inhibitors can be considered as a promising adjunct to TCs. Recent advances in the pharmacotherapeutic paradigm of atopic diseases exploring the therapeutic dominance of nanocarrier-mediated delivery is also discussed in this evidence-based review with regard to the treatment of AD. The present review summarizes the available clinical evidence, highlighting the current and emerging trends in the treatment of AD and providing evidence-based recommendations for the clinicians and health care professionals. Available evidence for the management of pediatric and adult atopic dermatitis (AD; atopic eczema) of all severities is explored. The management of other types of dermatitis, such as irritant contact dermatitis, seborrheic dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, and allergic contact dermatitis are outside the scope of current review article. The presented studies were appraised using a unified system called the "Strength of Recommendation Taxonomy (SORT)", which was developed by the editors of several US family medicine and primary care journals (i.e., American Family Physician, Family Medicine, Journal of Family Practice, and BMJ USA).1 The searched studies were graded using a 3-point scale based on the quality of methodology (e.g., randomized control trial, case control series, clinical cohort studies, case series, etc.) and key emphasis of the trial (i.e., diagnosis, treatment/prevention/ screening, or prognosis) as follows:
I. Good-quality patient-oriented evidence (i.e., evidence assessing consequences that matter to patients: mortality, morbidity, improvement in signs and symptom, quality of life, and socioeconomic factors);
II. Limited-quality patient-oriented evidence; and
III. Other evidence such as consensus guidelines, expert opinion, case control trial, or disease-related information.
Recommendations for nonpharmacological and pharmacological approaches were established based on the best available evidence and are graded as follows:
A. Recommendations based on consistent and good-quality patient-oriented evidence;
B. Recommendations based on inconsistent or limited-quality patient-oriented evidence; and
C. Recommendations based on consensus, expert opinion, case control evidence, or disease-related information.

CITADO POR
  1. Patrizi Annalisa, Neri Iria, Ricci Giampaolo, Cipriani Francesca, Ravaioli Giulia Maria, Advances in pharmacotherapeutic management of common skin diseases in neonates and infants, Expert Opinion on Pharmacotherapy, 18, 7, 2017. Crossref

  2. Md Shadab, Kuldeep Singh Jasvinder Kaur A/P, Waqas Muhammad, Pandey Manisha, Choudhury Hira, Habib Haroon, Hussain Fahad, Hussain Zahid, Nanoencapsulation of betamethasone valerate using high pressure homogenization–solvent evaporation technique: optimization of formulation and process parameters for efficient dermal targeting, Drug Development and Industrial Pharmacy, 45, 2, 2019. Crossref

  3. Zhuo Fan, Abourehab Mohammed A.S., Hussain Zahid, Hyaluronic acid decorated tacrolimus-loaded nanoparticles: Efficient approach to maximize dermal targeting and anti-dermatitis efficacy, Carbohydrate Polymers, 197, 2018. Crossref

  4. Pandey Manisha, Choudhury Hira, Gunasegaran Tarakini A. P., Nathan Saranyah Shanmugah, Md Shadab, Gorain Bapi, Tripathy Minaketan, Hussain Zahid, Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting, Drug Delivery and Translational Research, 9, 2, 2019. Crossref

  5. Simon Dagmar, Nobbe Stephan, Nägeli Mirjam, Barysch Marjam, Kunz Michael, Borelli Siegfried, Hasan-Ali Omar, Wildi Eckhart, Gasser Urs Erwin, Short- and long-term effects of two emollients on itching and skin restoration in xerotic eczema, Dermatologic Therapy, 31, 6, 2018. Crossref

  6. Fang Gang, Zhang Qinghuai, Pang Yuzhou, Thu Hnin Ei, Hussain Zahid, Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy, Journal of Controlled Release, 303, 2019. Crossref

  7. Damiani Giovanni, Eggenhöffner Roberto, Pigatto Paolo Daniele Maria, Bragazzi Nicola Luigi, Nanotechnology meets atopic dermatitis: Current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature, Bioactive Materials, 4, 2019. Crossref

  8. Ramos Campos Estefânia Vangelie, Proença Patrícia Luiza De Freitas, Doretto-Silva Lorena, Andrade-Oliveira Vinicius, Fraceto Leonardo Fernandes, de Araujo Daniele Ribeiro, Trends in nanoformulations for atopic dermatitis treatment, Expert Opinion on Drug Delivery, 17, 11, 2020. Crossref

  9. Luk David, Hon Kam Lun Ellis, Dizon Maria Victoria C., Leong Kin-Fon, Tay Yong-Kwang, Koh Mark Jean-Aan, Chandran Nisha Suyien, Wananukul Siriwan, Chatproedprai Susheera, Luger Thomas, Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia, Dermatology and Therapy, 11, 1, 2021. Crossref

  10. Hussain Zahid, Thu Hnin Ei, Shuid Ahmad Nazrun, Kesharwani Prashant, Khan Shahzeb, Hussain Fahad, Phytotherapeutic potential of natural herbal medicines for the treatment of mild-to-severe atopic dermatitis: A review of human clinical studies, Biomedicine & Pharmacotherapy, 93, 2017. Crossref

  11. Singh Apoorva, Nimisha , A Comprehensive Review of Therapeutic Approaches Available for the Treatment of Dermatitis, Recent Patents on Nanotechnology, 16, 3, 2022. Crossref

  12. Hussain Zahid, Pandey Manisha, Choudhury Hira, Ying Pang Cheau, Xian Tan Mei, Kaur Tassjir, Jia Gan Wei, Gorain Bapi, Hyaluronic acid functionalized nanoparticles for simultaneous delivery of curcumin and resveratrol for management of chronic diabetic wounds: Fabrication, characterization, stability and in vitro release kinetics, Journal of Drug Delivery Science and Technology, 57, 2020. Crossref

  13. Kim Kyeong-Min, Kim So-Yeon, Mony Tamanna Jahan, Bae Ho Jung, Choi Seung-Hyuk, Choi Yu-Yeong, An Ju-Yeon, Kim Hyun-Jeong, Cho Ye Eun, Sowndhararajan Kandhasamy, Park Se Jin, Moringa concanensis L. Alleviates DNCB-Induced Atopic Dermatitis-like Symptoms by Inhibiting NLRP3 Inflammasome-Mediated IL-1β in BALB/c Mice, Pharmaceuticals, 15, 10, 2022. Crossref

  14. IBRAHIM SALIZATUL ILYANA, MATMIN JUAN, HAIRUL NURIANA MUNIRAH, ABDUL MAJEED ABU BAKAR, ENHANCING EMOLLIENT PROPERTIES OF NATURAL AND STRUCTURED VIRGIN COCONUT OIL CREAMS ON SKIN CONDITIONS USING NON-INVASIVE SKIN BIOPHYSICAL METHODS, Malaysian Applied Biology, 51, 4, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain